Pressure BioSciences Says Additional Data Presented Showing PCT Platform Gives New Insights For Potential Biomarker Discovery Tool

Aug. 02, 2013 2:13 PM ETPBIO
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Short Only

Contributor Since 2009

Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London. Proactiveinvestors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of listed companies across the globe daily. We are one of the fastest growing financial media portals in the world. The group also operates hugely successful “investor forums” where three or four companies present to an audience of high net sophisticated investors, fund managers, hedge funds, private client brokers and analysts. Ian Mclelland founded Proactiveinvestors in 2006 as a way to channel his own views on companies small and mid-cap public companies. What started as a hobby quickly turned into a full time job as the website's readership exploded. One2One forums were added later in 2006, and within two years the company had expanded its operations into Canada and Australia. In 2009 the company expanded into Germany and finally into the US in 2010. Proactiveinvestors is now one of the fastest growing global financial media organizations in the world receiving more than one million visitors per month, with investor forums held across the globe on a regular basis.

Pressure BioSciences (OTCQB:PBIO) has announced that additional data, presented at the 27th annual symposium of the Protein Society held last month in Boston, has helped support the use of the company's pressure cycling technology (PCT) platform for generating information on proteins that other methods can't.

In emailed comments, the company's CEO, Richard Schumacher, said this should result in additional sales of PCT systems as other scientists will also want to have this advanced tool, resulting in better diagnostics and therapeutics globally.

At the Protein Society symposium this year, researchers from UCLA reported on the development of an improved Electron Paramagnetic Resonance (EPR) system based on the use of high pressure. The system, combined - for the first time ever - two "cutting-edge" EPR methods, according to the company's statement, including site directed spin labeling (OTC:SDSL) and double electronelectron resonance (OTCPK:DEER).

"The study of proteins under pressure by EPR and other spectroscopic techniques, such as Nuclear Magnetic Resonance (NMR), has the potential to greatly improve our understanding of the structure and function of proteins. This information could subsequently provide new insights into such important areas as biomarker discovery and rational drug design, and play an important role in the discovery process," said the senior author of the study and a professor at UCLA, Dr. Wayne L. Hubbell.

"This strategy allowed the investigation of dynamic events in proteins that would be difficult or even impossible to study by conventional EPR technology," added Pressure BioSciences.

The use of EPR systems have been shown to provide key information on the structure, flexibility and function of proteins, according to the company's release, which is crucial to the development of new and improved diagnostics, therapeutics and vaccines.

"We believe these and other data reported by researchers using pressure-based EPR and NMR systems strongly indicate that PCT can enhance the recovery, detection, and measurement of proteins from a wide variety of samples," said Schumacher in the statement Thursday.

"We further believe that the advantages of pressure-based spectroscopic methods are just now beginning to be realized by scientists, and that as the body of data continues to grow from high pressure-based spectroscopic studies, that PBI has the potential to become a major provider of high pressure equipment into the exciting and growing spectroscopy area."

In June, the company, which is developing the PCT platform for multiple applications, closed the third and final tranche of a convertible preferred stock and warrants financing, raising a total of $2.03 million, slightly surpassing its inital $2 million goal. The company said at the time that its next goal is to significantly strengthen its cash position before year-end

Earlier that month, Pressure BioSciences said it had a new high throughput (HT) design for its patented pressure cycling technology (PCT) that would integrate its platform with the automated HT sample preparation and analytical system formats installed in thousands of research labs globally. The company said it believes that this breakthrough has the potential to "significantly accelerate" its growth in existing and new PCT-based applications and products, as well as in its ability to attract new strategic partnerships and its overall revenue ramp-up. It reported a 21 per cent increase year-over-year in revenue with PCT products in May, and said it expects to release several new products in 2013.

Pressure BioSciences is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on PCT, which has several applications in the estimated $6 billion life sciences sample preparation market. Other applications for PCT include mass spectrometry, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.